Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Xgeva by Amgen for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis): Likelihood of Approval
Xgeva is under clinical development by Amgen and currently in Phase II for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell...